Navigation Links
Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
Date:5/9/2011

BLUE BELL, Pa., May 9, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV). These results were presented at the 15th Annual Conference on Women's Health Care Issues, hosted in New York by the International Infectious Disease Society for Obstetrics and Gynecology-USA, by Mark Bagarazzi, MD, Inovio's chief medical officer.

The data were generated through a long-term assessment of participants in Inovio's Phase I study of 18 adult females with moderate or severe cervical intraepithelial neoplasia (CIN 2/3), a high-grade premalignant lesion that may lead to cervical cancer. This study was designed to assess immune responses generated by and safety of the vaccine.

In this study, 72% of vaccinated subjects (13 of 18) developed significant antigen-specific T-cell responses during the first four months of treatment (each patient was vaccinated at months 0, 1, and 3) by standardized interferon-γ ELISpot assay. The third and highest dose group displayed the strongest level of T cell responses, with 83% (5 of 6) positive responders. The level of T cell responses in positive responders ranged from 100 to over 5000 spot forming units (SFU) per million cells when measured after overnight stimulation in the standardized ELISpot assay. In contrast, competing vaccine approaches targeting HPV therapy have consistently shown sub-100 SFU levels even when using more sensitive assays.

This newly reported data evaluated 11 of 13 pos
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
3. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
4. Vanda Pharmaceuticals Reports First Quarter 2011 Results
5. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
6. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
10. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
11. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
(Date:5/29/2015)... Columbia, Pa. (PRWEB) May 29, 2015 ... Thermal Product Solutions with a request to design ... remove excess moisture from prescription medications being produced ... custom solution that includes a robotic gantry, heat-saving ... positions and dries trays of 3D-printed pills to ...
(Date:5/29/2015)... , May 29, 2015  Caris Life ... on fulfilling the promise of precision medicine, today ... that demonstrate the clinical utility of Caris Molecular ... profiling service, in helping to identify targeted treatment ... In each of the studies, results of which ...
(Date:5/29/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... New York City . The presentation ... Thursday, June 4, 2015, at 11:00 AM Eastern Time, and ...
Breaking Biology Technology:Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... , NEW YORK, Dec. 4 Stemline Therapeutics, Inc. ... agents, SL-401 and SL-501, in both in vitro and ... for poster presentation at the upcoming 51st Annual Meeting of the ... from December 5-8, 2009. The poster will be presented by Stemline,s ...
... , HOUSTON, Dec. 3 ... updated its facility to offer patients a second surgical option, ... that it currently performs. The first sleeve gastrectomy procedure at the ... on October 20, 2009. The patient is reported as doing ...
... , ... (OTC Bulletin Board: ACCP), today provided ... FDA approved treatment for oral mucositis, a debilitating side effect ... Access, partner, SpePharm, in six European countries, including the UK, ...
Cached Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Center for Molecular Medicine (MDC) Berlin-Buch have gained new ... Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit ... damage within seconds, activates the transcription factor NF-kappaB, a ... program, which blocks programmed cell death. The activation of ...
... Andrews in the UK have found that the color of ... appear, and have found that diet may be crucial to ... in the December issue of Springer,s International Journal of ... of 54 Caucasian participants of both sexes were asked to ...
... While mothers have known that feeding their kids milk builds ... Institute at Intermountain Medical Center in Salt Lake City suggests ... as well and that inadequate levels of the vitamin ... and death, even among people who,ve never had heart disease. ...
Cached Biology News:How cells tolerate DNA damage -- start signal for cell survival program identified 2How cells tolerate DNA damage -- start signal for cell survival program identified 3Skin color gives clues to health 2New study links vitamin D deficiency to cardiovascular disease and death 2New study links vitamin D deficiency to cardiovascular disease and death 3
... Detection System is intended for use in ... by an in-house validated method for in ... target of interest. • ... a hybridization capture assay designed to detect ...
... maximum packaging efficiencies of cDNA and genomic DNA ... a test insert with Novagen's l vector arms, ... 10^8 pfu/g ligated l control DNA) are typically ... use; simply add up to 5 g of ...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: